Supplementary Materials

Supplementary Material for:

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

Lecia V. Sequist,* Belinda A. Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B. Turke, Panos Fidias, Kristin Bergethon, Alice T. Shaw, Scott Gettinger, Arjola K. Cosper, Sara Akhavanfard, Rebecca S. Heist, Jennifer Temel, James G. Christensen, John C. Wain, Thomas J. Lynch, Kathy Vernovsky, Eugene J. Mark, Michael Lanuti, Anthony J. Iafrate, Mari Mino-Kenudson, Jeffrey A. Engelman*

*To whom correspondence should be addressed. E-mail: lvsequist{at}partners.org (L.V.S.); jengelman{at}partners.org (J.A.E.)

Published 23 March 2011, Sci. Transl. Med. 3, 75ra26 (2011)
DOI: 10.1126/scitranslmed.3002003

This PDF file includes:

  • Fig. S1. Percent change in measurable disease, by patient.
  • Fig. S2. Amplification of the T790M allele in tumors with EGFR amplification.
  • Fig. S3. The overall distribution of the genetic and histological findings in the resistant biopsies.
  • Table S1. Detailed results for 37 paired specimens with TKI resistance.
  • Table S2. Mutations tested in SNaPshot version I.
  • Table S3. Results from first autopsy case.
  • Table S4. Results from second autopsy case.

[Download PDF]